In the oncogenic BRAF-V600E mouse model, deletion of the tumour suppressor SMAD4 promoted rapid development and the progression of serrated tumours, and SMAD4 mutations co-occurred with BRAF-V600E mutations in human patient tumours [42]. This evidence concerns the gene SMAD4 and neoplasm.